Vitro Diagnostics Inc (fka VODG)

[Potse]

Anticipated revenue increase, MSC-Gro statement.....

From the August 12 press release....

Pete Shuster, a Director of Vitro Biopharma and the CEO & founder of Neuromics said, “We are pleased to announce this solid revenue growth. In the coming quarters, we anticipate revenue growth to continue to accelerate well beyond the 4-fold increase documented in this release. Our shareholders should expect announcement of profits by end of Q1, 2015.

Pete Shuster's statement regarding an expectation of profits by the end of Q1 2015 suggests that VODG is anticipating a relatively large increase in quarterly revenues over the course of the next couple/few quarters.

Based on the Q3 pre-announcement in the above press release, VODG continues to experience sequential revenue growth in fiscal 2014.....

Q1: $26K
Q2: $35K
Q3: $47K

I'm guessing that VODG's operating expenses probably will not show any significant decrease during the next few quarters. So assuming VODG achieves profitability as a result of operational activity (and not as a result of debt forgiveness), Shuster's statement probably implies that VODG expects its quarterly revenue level will double/triple ($100-200K) by the first quarter or two of fiscal 2015.

Also somewhat noteworthy in this press release is the paragraph devoted to MSC-Gro Media and its potential for use in human clinical applications. It has been mentioned in previous SEC filings, but to the best of my recall this may have been the first time it has been a prominent part of any press release. So that paragraph and Musick also mentioning it in his "commentary" section of the press release probably suggests VODG may be getting closer to making a regulatory application (510K), or at the very least strengthening its efforts in that area......

Our MSC-Gro(tm) Media for cell culture of MSCs and other primary cell lines has numerous competitive advantages including increased cellular recovery and potency when compared to other leading suppliers. We are leveraging this position to attain full regulatory compliance and increased manufacturing capacity for use of this media in the expansion of patient-specific MSCs for clinical applications. Human MSC transplantation is gaining positive results from numerous studies of efficacy & safety especially in the treatment of osteoarthritis, a common condition that often leads to joint replacement. We are in discussions with various third parties representing significant commercial opportunities for us to also recognize increased revenue through this initiative.